Home
This site is intended for healthcare professionals

Primary Care Obesity Roadmap Australia: Module 4 Patient Centric Monitoring

Share

Description

This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Join expert Ralph Audehm, MD, for a practical, case-based exploration of long-term, patient-centric monitoring strategies in primary care obesity management. This session examines how to navigate anti-obesity medication adherence, manage gastrointestinal side effects and blood pressure changes, adjust concomitant weight-promoting medications, and implement structured shared decision-making pathways to sustain long-term treatment outcomes.

Session Highlights

  • Establish long-term adherence plans from medication initiation, recognizing obesity as a chronic condition that requires continuous management and proactive counseling on weight rebound risks.
  • Apply phase-specific strategies to prevent and manage gastrointestinal side effects during GLP-1-based therapy escalation, utilizing dietary adjustments, hydration, and tailored dose titration.
  • Evaluate lightheadedness or low blood pressure during therapy as potential triggers to reassess hydration status, blood glucose, and concomitant antihypertensive or antidiabetic treatments.
  • Review concomitant patient medications to identify weight-promoting agents and transition to non-weight-promoting therapeutic alternatives where appropriate.

This is Module Four of Four, See Modules One, Two and Three Here.

Prefer to read? see our Key Clinical Summary Here

Who Should Watch

This activity is intended for primary care providers, nurse practitioners, physician assistants/associates, pharmacists, and other healthcare providers who care for patients with obesity.

Faculty

Dr Ralph Audehm is a general practitioner who graduated from Melbourne University in 1984 and has worked for over 25 years in general practice. He is experienced in managing all types of patients. He obtained a Diploma from the Royal Australian College of Obstetricians and Gynaecologists in 1987 and is an Honorary Clinical Associate Professor at the Department of General Practice, University of Melbourne. He has had a long-standing interest in the management of chronic conditions in General Practice especially diabetes and heart disease.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant financial relationships are mitigated according to Partners policies.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr Ralph Audehm, faculty for this educational activity, has the following relevant financial relationships: Advisory Board and Consultant for AstraZeneca, Boehringer Ingelheim, Lilly and NovoNordisk.

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Associate Continuing Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.

Pharmacy Continuing Education

Partners designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number - JA4008073-9999-26-295-H01-P

Type of Activity: Knowledge

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information

There is no fee for this educational activity.

This continuing education activity is active starting September 10th 2026, and will expire on August 4th 2027.

Estimated time to complete this activity: 15 Minutes

Learning objectives

  1. Employ bias-aware communication and structured shared decision making (SDM) at the point of diagnosis, utilizing the patient's specific metabolic and mechanical complications to collaboratively set function-based goals for people with obesity, demonstrating correct application in > 75% of post-activity case assessments.

  2. Initiate guideline-concordant treatment plans – integrating pharmacotherapy, structured lifestyle interventions, and surgical referrals – while implementing workflows to monitor physical function and preserve body composition, achieving appropriate treatment decisions in > 75% of simulation scenarios.

  3. Apply structured reassessment algorithms to determine treatment efficacy, true therapeutic non-response amid weight plateaus, and timely treatment escalations in > 70% of longitudinal case exercises.

  4. Formulate proactive long-term adherence pathways — including proactive side-effect mitigation, the timely review of concomitant medications, and a patient-centered review of therapeutic options in > 75% of applied decision activities.

Similar communities

View all

Similar events and on demand videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So, Paul, what do you usually do first when a patient reports nausea, lightheadedness after starting weekly GLP one based therapy? Do you stop the therapy? Do you reassure and continue therapy as planned, slow dose titration, review medications, BP and glucose, arrange rapid follow-up? OK. So a patient with obesity, type 2 diabetes, and hypertension presents 6 weeks after starting lifestyle support, um, plus locally GLP-1 based therapy. Nausea started during dose escalation with occasional vomiting. He does feel lightheaded, um, he's had two low home BP readings. Um, he is eating smaller portions, so it, it looks like he's not pushing himself, so he did listen to us when we told him to be aware of this and to use smaller portions, less, you know, uh, not spicy and low fat, um, but he's worried that he's not doing so well and wants to know, should he stop the new medication. Now medication persistence um is something that's, um, we know people won't stay on a lot of these medications forever. Having said that, um, most of my people on type 2 diabetes on a GLP 1, have persisted the whole time through. And they've done incredibly well. I mean I've had a few non-responders, um, and I've had a few people who have managed to stay at half dose, but they were obviously very sensitive because they lost, um, a decent amount of weight, but, um, I find my people with type 2 diabetes are far more likely to persist, uh, with these medications because the feedback they get from all the benefits, um, I really motivates them. But you can see here that, You know, ah, things like, um, Orlistat, I don't know if you still use it, but, um, it's a very hard drug to, to use all the time, um, topiramate by itself, ah, you know, we have 30 to, you know, again, a lot of people will stop it due to the side effects and fatigue. Um, but even with, um, the simaglatide, ah, we can see that, in fact, um, people do stop it if it's purely for weight loss. Now in Australia, most of that's because of the cost, um, but, you know, it's interesting, so in Australia, um, simaglatide is subsidized, so it's much, much cheaper for people living with type 2 diabetes. And I can tell you they persist with it because of the um the beneficial impact, but we know a lot of people will stop their medications, and of course we've also worked out that when they stop their medications, that they regain, and of course this is one of the things that we need to be aware of that obesity is a chronic condition, it's, Going to be there, you know, we don't stop BP medications once people get to normotension, because we know it's gonna rebound and unfortunately this is what happens to people ah with obesity. Now, having said that, look, you do have occasional people who seem to go very well once they're off medication, but they're very small number, um, most of my patients regain, um, and so it's something that they need to be aware of. And so it's not their fault, you know, we've, this is part of that metabolic adaptation and if we're withdrawing the thing that's helping them, yes, we know it's going to recur, and they need to be aware of that when they start the medication because now we need to be talking about this being lifelong therapy, um, because when you stop it we know it's going to recur. These are the common side effects um of the GLP ones, we're all very familiar with it, the nausea, I mean I, I don't see much diarrhea, but the nausea absolutely um. And occasionally constipation, I have had some people vomit especially when they've pushed how much they're eating, um, but you know, most of these side effects settle down um within a week. Sometimes two if you're unlucky, but they are really self-limiting and most people can persist. I have had some people like I say who I can't get past the 0.5 of the maglatide, um, because of the nausea, but, you know, again, if it works for them, that's fine. So for the nausea, small meals often, making sure they have plenty of fluids, avoid those strong smells, um, ginger maybe, um but I just tell people just have a small snack like a, they've got here crackers or or a dry biscuit first thing in the morning, just, just a little bit, a couple of mouthfuls, um. Well the diarrhea, um we can manage that, but again it's usually self limiting, but making sure that they do maintain their hydration, especially cos this guy's a little bit hypotensive and, you know, he's uh obviously got diarrhea, so making sure that he is well hydrated, um. Again, with the vomiting, uh, I haven't had to use anti-Meggs cos I think once you explain to people what's going on, the vast majority will wait for the side effects to go and of course with constipation, fluid and increasing the fiber in the diet. And again, many of these things will be really helped uh by having access to a dietician if you can. Um, so, um, I think this is a really good one in that before you start the medication, actually set down realistic expectations. I think that's important, um, especially working out what goals that we're actually going for, but I always go through the gastrointestinal side effects because they are so common. I warn them and I tell them, you know, um, on that first day, just be very careful, you know, maybe do it on a Saturday. Um, and then with the dose escalation, you know, I know when they go to a high dose, they're going to feel it just again, so I tell them, I pre-warn them, and of course I'm seeing them at the 4 week mark as well to just to remind them. And you know basically most people um will get there, I haven't had to use the anti-mexic cos I think you know when you tell people and they put in place what they need to ah usually they do OK. Well these are some of the medications ah that can cause weight gain, um, and the ones that, you know, these are the ones that, you know, I see the most, um, and it's a tragedy when people have to be on these and now we've got something that we can use to treat them, but prior to this, managing that weight gain um ah was really quite difficult, um, but of course, you know, all these drugs can have some impact. And, but what we're talking about really, um, you know, we're we're going to talk to the patient about what it is, um, the, the benefits or after, um, and of course the, the risks, we're going to clarify those goals and I think that's really important at the outset. You know, what's your target weight, how much are you going to lose? Let's talk about percentages, um, or if you have a kilo, let's write down the kilo. Then you're going to plan and you know you've given the choice of agents and the you know the very low calorie diets, ah to the person in front of you, they've chosen whatever and then review and I say early review in the beginning, and then spacing it out and 12 weeks. I think it's a little bit too long, um, from my point of view, um, but if you've got a team around you, such as a nurse dietician and exercise physiology who's part of the team, well then maybe you won't need to see them, um, that early. So question 9, what's the best immediate response today? Do you refer straight back to the specialist uh without further assessment, reassure them that nausea means the treatment's working and continue unchanged, stop the GLP-1 based therapy immediately, increase fluids and review again again at the next routine visit, assess symptoms, hydration, BP, glucose dose, and medications. And of course it, you know, it's going to be assessing the symptoms, the hydration, uh looking at his BP and BP medications, make sure he's um er doing everything appropriately. Um Two weeks later, his nausea has improved, but he's now reluctant to continue treatment in case the symptoms return. What is the best adherence plan, so he can continue without further follow-up unless symptoms return, stop therapy to avoid future side effects, agree a slower titration plan with symptom and medication review, restart rapid titration to reach the target dose quickly, focus only on lifestyle change until all these symptoms disappear. And of course, as we've talked about before, Individualizing that um titration um becomes really important, so slow it down, take your time. So, you know, he had, he had dizziness, so you may want to adjust his BP medications and make sure he's adequately hydrated. Dose escalation is paused and sometimes you may even step it back one, Reviewing his medications, and we've done a slower.